WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130080
CAS#: N/A
Description: KS-19 is a KRAS G12C inhibitor. KS-19 has been shown to exhibit higher antiproliferative activity (IC50 = 0.66 μM) as compared to ARS-1620 (1.32 μM), decrease KRAS G12C-GTP and pErk levels, and was able to suppress NCI-H358 tumor growth to a higher degree.
Hodoodo Cat#: H130080
Name: KS-19
CAS#: N/A
Chemical Formula: C24H18Cl2FN5O5
Exact Mass: 545.07
Molecular Weight: 546.340
Elemental Analysis: C, 52.76; H, 3.32; Cl, 12.98; F, 3.48; N, 12.82; O, 14.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KS-19; KS 19; KS19
IUPAC/Chemical Name: (4-(6-Chloro-7-(5-chloro-2-methoxyphenyl)-8-fluoroquinazolin-4-yl)piperazin-1-yl)(5-nitrofuran-2-yl)methanone
InChi Key: AIRAONOHNMWJKZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H18Cl2FN5O5/c1-36-17-3-2-13(25)10-14(17)20-16(26)11-15-22(21(20)27)28-12-29-23(15)30-6-8-31(9-7-30)24(33)18-4-5-19(37-18)32(34)35/h2-5,10-12H,6-9H2,1H3
SMILES Code: O=C(N1CCN(C2=C3C=C(Cl)C(C4=CC(Cl)=CC=C4OC)=C(F)C3=NC=N2)CC1)C5=CC=C([N+]([O-])=O)O5
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 546.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Li L, Zhao H, Peng X, Liu J, Mai R, Chen J, Lin L, Chen T, Yan J, Shi J, Chen J. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. Bioorg Med Chem. 2022 Oct 1;71:116962. doi: 10.1016/j.bmc.2022.116962. Epub 2022 Aug 5. PMID: 35987104.